Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.76 |
| ▸ | PKM | P14618 | 5/20 | 0.76 |
| ▸ | HTT | P42858 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1956663 | 0.97 | ALDH1A1 (0.70) | ALDH1A1PKMHTTPOLBKMT2A | |
| SCHEMBL23217199 | 0.94 | PKM (0.74) | ALDH1A1PKMHTTPOLBKMT2A | |
| SCHEMBL3976265 | 0.92 | PKM (0.69) | ALDH1A1PKMHTTPOLBKMT2A | |
| Bromide SCHEMBL1159786 | 0.92 | PKM (0.72) | ALDH1A1PKMHTTPOLBKMT2A | |
| SCHEMBL6013980 | 0.92 | PKM (0.71) | ALDH1A1PKMHTTPOLBKMT2A | |
| SCHEMBL3977980 | 0.92 | PKM (0.71) | ALDH1A1PKMHTTPOLBKMT2A | |
| Bromide SCHEMBL3970603 | 0.91 | PKM (0.69) | ALDH1A1PKMHTTPOLBKMT2A | |
| SCHEMBL5955341 | 0.91 | MAPT (0.69) | ALDH1A1PKMHTTPOLBKMT2A | |
| SCHEMBL651924 | 0.91 | MAPT (0.69) | ALDH1A1PKMHTTPOLBKMT2A | |
| SCHEMBL9122576 | 0.91 | MAPT (0.69) | ALDH1A1PKMHTTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344608-B1 | A PROCESS FOR THE PREPARATION OF XYLENE LINKED CYCLAM COMPOUNDS | FRESENIUS KABI ONCOLOGY LTD (IN) | 2019-10-23 | — | — | EP | disclosed |
| WO-2017037639-A1 | A PROCESS FOR THE PREPARATION OF XYLENE LINKED CYCLAM COMPOUNDS | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2017-03-09 | — | — | WO | disclosed |
| EP-2163553-B1 | ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO LTD (CN) | 2013-12-25 | — | — | EP | disclosed |
| US-8420626-B2 | Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2013-04-16 | — | — | US | disclosed |
| US-20100179116-A1 | Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2010-07-15 | — | — | US | disclosed |
| EP-2163553-A1 | ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | Beijing Molecule Science and Technology Co., Ltd. (CN) | 2010-03-17 | — | — | EP | disclosed |
| EP-1133291-B1 | CYCLIC POLYAMINES FOR TREATING THROMBOCYTOPENIA | SMITHKLINE BEECHAM CORP (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6498155-B1 | SUCH AS 1,1'-(1,4-PHENYLENEBIS(METHYLENE))BIS(1,4,8,11-TETRAAZACYCLOTETRADECANE); THROMBOPOIETIN RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-5800834-A | Liquisolid systems and methods of preparing same | HYGROSOL PHARMACEUTICAL CORP. | 1998-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179116-A1 | Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof | SRM, SP1, SMS | ALDH1A1 1826/4885PKM 119/4885HTT 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.